GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » NonCurrent Deferred Liabilities

Telomir Pharmaceuticals (Telomir Pharmaceuticals) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Telomir Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Telomir Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

The historical data trend for Telomir Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals NonCurrent Deferred Liabilities Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - -

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only - - - - -

Telomir Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines